Literature DB >> 18070704

The multidisciplinary management of gastrointestinal cancer. The use of molecular markers in the diagnosis and treatment of colorectal cancer.

Sabine Tejpar1.   

Abstract

Rapidly growing insights into the molecular biology of colorectal cancer led to high hopes for the identification of molecular markers to be used in optimised and tailored treatment regimens for this disorder. However, no molecular marker has yet made it into daily practice. In this review we will discuss some of the potential molecular markers, focus on the lessons learnt from marker development and identify strategies for the future.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18070704     DOI： 10.1016/j.bpg.2007.10.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN： 1521-6918            Impact factor:   3.043


  8 in total

Review 1.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

2.  Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer.

Authors:  Chin-Shaw Stella Tsai; Hung-Chang Chen; Jai-Nien Tung; Shung-Sheng Tsou; Tang-Yi Tsao; Ching-Fong Liao; Ying-Chun Chen; Chi-Yuan Yeh; Kun-Tu Yeh; Ming-Chung Jiang
Journal:  Am J Pathol       Date:  2010-02-11       Impact factor: 4.307

3.  The pattern of epidermal growth factor receptor variation with disease progression and aggressiveness in colorectal cancer depends on tumor location.

Authors:  Petros C Papagiorgis; Adamantia E Zizi; Sophia Tseleni; Ioannis N Oikonomakis; Nikolaos I Nikiteas
Journal:  Oncol Lett       Date:  2012-02-28       Impact factor: 2.967

4.  Prognostic value of serum neutrophil gelatinase-associated lipocalin in metastatic and nonmetastatic colorectal cancer.

Authors:  Josep Martí; Josep Fuster; Anna M Solà; Georgina Hotter; Rafael Molina; Amalia Pelegrina; Joana Ferrer; Ramon Deulofeu; Constantino Fondevila; Juan Carlos García-Valdecasas
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

5.  The expressions of stem cell markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in bladder, colon, and prostate cancer, and certain cancer cell lines.

Authors:  Sabrieh Amini; Fardin Fathi; Jafar Mobalegi; Heshmatollah Sofimajidpour; Tayyeb Ghadimi
Journal:  Anat Cell Biol       Date:  2014-03-13

6.  Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells.

Authors:  Suman Suman; Trinath P Das; Suman Sirimulla; Houda Alatassi; Murali K Ankem; Chendil Damodaran
Journal:  Oncotarget       Date:  2016-03-22

7.  Metastatic Tissue Proteomic Profiling Predicts 5-Year Outcomes in Patients with Colorectal Liver Metastases.

Authors:  Santiago Marfà; Josep Marti; Adalgiza Reyes; Gregori Casals; Guillermo Fernández-Varo; Silvia Carvajal; J C García-Valdecasas; Josep Fuster; Wladimiro Jiménez
Journal:  Transl Oncol       Date:  2016-10       Impact factor: 4.243

8.  The Role of VEGFA, COX2, HUR and CUGBP2 in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients.

Authors:  Henrikas Pauzas; Ugne Gyvyte; Tadas Latkauskas; Laura Kairevice; Paulius Lizdenis; Saulius Svagzdys; Erika Birgiolaite; Irma Kuliaviene; Juozas Kupcinskas; Algimantas Tamelis
Journal:  Medicina (Kaunas)       Date:  2020-04-22       Impact factor: 2.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.